Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Go up to the sticky posts and click on Provectus filings...It comes up as the first filing...
Great Post Fruno Thanks!
The Big boys are involved now IMO and they are shaking the tree's to get people like yourself to fall out of them so they can scoop up your shares. It looks to me as though its working perfectly for them.
Thanks for filling us in Tom...
You imply this is over. It is far from over... You are just playing into his hands (on purpose?) crying the sky is falling...
I wouldn't be surprised if some fund or funds are using this to grab a bunch of shares he is shaking loose...
It was written that way on the Website long before the FDA even had such a designation thats why...
Provectus Oldie but Goodie maybe time for a replay...
I agree but there are a lot of eyes here now looking for any tiny little chink in the armor....
IMO it is nothing...
If he did sell maybe because he did not have the $25,000 to spare and why throw away the $50,000 that he recieved? Now that would be stupid...
He exercised options...
Do you have a link to such press release?
PROVECTUS BIOPHARMACEUTICALS TO CELEBRATE NYSE MKT LISTING WITH OPENING BELL CEREMONY
PROVECTUS TO RING OPENING BELL ON THURSDAY, MAY 22, 2014
KNOXVILLE, TN, May 19, 2014 — Provectus Biopharmaceuticals, Inc. (PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced today that its CEO and Chairman Dr. Craig Dees, PhD, its CTO Dr. Eric Wachter, PhD and its CFO and COO Peter Culpepper, along with Alfred E. Smith, IV, Lead Independent Director of its Board, along with key advisors will ring The Opening Bell® at the New York Stock Exchange at 9:30 a.m. EDT on Thursday, May 22, 2014.
The ceremonial ringing of the bell celebrates the Company’s recent listing on May 16, 2014, when the Company’s common stock began trading on the NYSE MKT under its ticker symbol “PVCT.”
Provectus submitted an application in March 2014 to the FDA for breakthrough therapy designation for its novel oncology drug PV-10 based on the results from its phase 2 clinical study related to metastatic melanoma. The Company is researching efficacy of PV-10 for other indications, including liver and breast cancers.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 (a formulation of the small molecule ablative agent rose bengal disodium) is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
Simultaneously going for BTD in Breast Cancer... They already have done trials there also...
Nice post Tom and as usual your vision is appreciated... Thanks!
Just saw the first premarket order On the NYSE MKT go through @ $3.99...
Yes they are and you vote by buying shares...
The Risk may be high as you say but it goes way down on Friday with the new credibility of a real exchange to trade on. NYSE MKT as opposed to the Pink sheets...
Simple they are waiting for the NYSE to announce it... It is out of PVCT's hands...
No Particular part Buc... It is just one of the documents the NYSE requires before uplisting...
Nobody said all PVCT even has some Very little but some...
It is currently a OTCBB Stock most all institutions are not allowed to buy OTCBB. Once uplisting occurs and price moves up to their buying level that all changes...
No its a shelf offering replacing the much smaller existing shelf offering from lincoln capital. It is needed as a requirement of uplisting to the NYSE... And Yes it is a good thing...
Thanks Vorlon...
Roberti and White what can we do for you....
http://www.robertiwhite.com/record/
Thanks Vorlon...
I would agree with that... The boat was not a "Seagoing" vessel. Any rough water and it would have sunk. Whoever made the decision to buy that one had not been around boats much...
I always wondered why they called it the "Deep Scan" considering it did not do well in deep water...
Why does Cantor F keep coming up around PVCT? Is there something there?
the shorts are getting vocal... Something good this way comes... LOL
I was thinking about the fact I would not want to be the FDA guys here as people are dying waiting on their decision... I wonder if they even care?
I am sure there was no intentional malice meant... And I think this poster will post links and where it came from in the future. Most of us here frequent that site anyhow and realize what AGrossfarm brings to the table which is a lot...
Thanks Alan we appreciate your work!
they put out an 8K...
Borrowed From another Thread... Shows their intent is to "acquire"...
German drug giant Boehringer Ingelheim opens venture capital office in Cambridge
From 12/6/13 Boston Business Journal...
... ultimate goal is to find promising companies that could be acquired by BI, and says “we would like to go beyond what our parent company is already doing.” That means Heidecker will be looking at companies working on drugs in fields like dermatology, opthamology and regenerative medicine, as well as therapeutic vaccines aimed at cancers. He said he’s focused on “neglected areas” of disease, rather than large, competitive fields like chronic obstructive pulmonary disease
http://www.bizjournals.com/boston/blog/bioflash/2013/12/new-cambridge-vc-fund-head-looks-to.html
Starting to get very interesting...
Very interesting stuff in there about settlement of the management compensation lawsuit...All positive for the shareholder IMHO
What PR? The one thats just a correction From 2 weeks ago? If so I don't think so...
Trey Gowdy is awesome...I hope someday he runs for president. Can you imagine the debate...